Cadherin 5 Ιs a Significant Risk Factor for Hematogenous Recurrence and a Prognostic Factor in Locally Advanced Gastric Cancer

Inokuchi, Mikito; Higuchi, Kyoko; Takagi, Yoko; Tanioka, Toshiro; Nakagawa, Masatoshi; Gokita, Kentaro; Okuno, Keisuke; Kojima, Kazuyuki

doi:10.21873/anticanres.12141

Cited by 4 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, the dysregulation of CDH family members has been frequently reported. For instance, CDH5 expression was distinctly increased in gastric cancer and significantly associated with the recurrence [ 22 ]. Yang et al reported that the levels of CDH13 were distinctly upregulated in breast cancer [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Expression Profile and Prognostic Values of CDH Family Members in Lung Adenocarcinoma

2022

Disease Markers

View full text Add to dashboard Cite

Many studies have confirmed that the classical cadherin (CDH) gene family may be involved in the development and progression of various tumors. However, the comprehensive assays of CDH family members in lung adenocarcinoma (LUAD) were rarely reported. In this study, our group analyzed TCGA datasets and identified 18 dysregulated CDH members in LUAD specimens. Several CDH members exhibited an increased level in LUAD specimens, such as CDH1, CDH2, CDH3, CDH4, CDH5, CDH15, CDH16, CDH17, CDH18, CDH24, and CDH26. However, some others exhibited decreased levels in LUAD specimens. Correlation analysis revealed that most CDH members were negatively regulated by the methylation of CDH genes, leading to their low expression in LUAD tissues. Survival assays identified 16 survival-related CDH members in LUAD patients. More importantly, we further performed multivariate analysis to determine the prognostic value of the above CDH family members and found that the expression levels of CDH17, CDH19, and CDH24 were an independent prognostic biomarker of the LUAD outcome. Finally, the results of functional enrichments revealed that CDH members participated in several tumor-related pathways. Collectively, our findings suggest that CDH Family members functioned as oncogenes or antioncogenes in LUAD and may be a potential biomarker for this malignancy.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression Profile and Prognostic Values of CDH Family Members in Lung Adenocarcinoma

2022

Disease Markers

View full text Add to dashboard Cite

show abstract

“…[ 25 ] CDH5, also known as vascular endothelial cadherin, plays an important role in cell adhesion, inhibition of endothelial cell migration, and apoptosis. [ 26 ] CDH5 is highly expressed in various malignant tumor cells and has been shown to play a key role in GC progression, metastasis, and recurrence [ 26 , 27 ] . Thus, we inferred that GPR116 may contribute to tumor invasion and migration by promoting tumor angiogenesis.…”

Section: Discussionmentioning

confidence: 99%

“…It is highly expressed in tumor vascular endothelial cells and has become a potential target for therapy [25] . CDH5, also known as vascular endothelial cadherin, plays an important role in cell adhesion, inhibition of endothelial cell migration, and apoptosis [26] . CDH5 is highly expressed in various malignant tumor cells and has been shown to play a key role in GC progression, metastasis, and recurrence [26,27] .…”

Section: Discussionmentioning

confidence: 99%

GPR116 overexpression correlates with poor prognosis in gastric cancer

et al. 2021

View full text Add to dashboard Cite

The G protein-coupled receptor 116 (GPR116) is an adhesion subtype of the G protein-coupled receptor family and has been reported to be involved in tumorigenesis and cancer progression. Moreover, it has been shown to predict poor prognosis in breast and colorectal cancers. However, little is known about the role of GPR116 in gastric cancer (GC). In this study, we aimed to investigate the expression and clinical prognostic significance of GPR116 in GC.The mRNA expression levels of GPR116 in GC were analyzed using Gene Expression Omnibus and UALCAN databases, and GPR116 protein expression in GC tissues was detected using immunohistochemistry. The relationship between GPR116 expression and prognosis in patients with GC was analyzed and further validated using the Kaplan–Meier Plotter database. The correlation between GPR116 and the differentially expressed genes identified was analyzed using the LinkedOmics database. Gene set enrichment analysis was performed using WebGestalt. The results revealed that GPR116 expression was significantly upregulated in GC tissues, which was positively correlated with tumor node metastasis (TNM) staging and tumor invasion. Prognostic analysis suggested that high GPR116 expression contributed to poor overall survival in GC patients. Multivariate Cox analysis indicated that GPR116 overexpression was an independent prognostic indicator in patients with GC (HR = 1.855, 95% CI 1.021–3.370, P = .043). Enrichment analysis showed that GPR116 co-expression genes were mainly involved in extracellular matrix-receptor interaction, focal adhesion, cell adhesion, PI3K-Akt signaling, DNA replication, and cell cycle pathways. In conclusion, GPR116 was highly expressed in GC tissues and associated with poor prognosis in patients with GC, Thus GPR116 may be a novel prognostic marker and a potential therapeutic target for GC treatment.

show abstract

“…These pathways were classified into four groups based on the functional similarity of the cellular networks (Figure 6B). Specifically, Group 1 encompassed ANGPT, PDGF, CDH5, FN1, PECAM1, ESAM, GRN, SPP1 and Collagen signaling pathways, and are implicated in promoting tumor growth through angiogenesis, immune evasion, abnormal cell proliferation and differentiation [49][50][51][52][53][54][55][56][57] . Group 2 consisted of MIF, VEGF, CD46 and Laminin signaling pathways, which are associated with cell adhesion and migration to support metastasis [58][59][60][61] .…”

Section: Cellular Communication Network In Human Rb Subpopulationsmentioning

confidence: 99%

Spatial transcriptomic profiling of human retinoblastoma

Wang,

Hung,

Urrutia-Cabrera

et al. 2024

Preprint

View full text Add to dashboard Cite

Retinoblastoma (RB) represents one of the most prevalent intraocular cancers in children. Understanding the tumor heterogeneity in RB is important to design better targeted therapies. Here we used spatial transcriptomic to profile human retina and RB tumor to comprehensively dissect the spatial cell-cell communication networks. We found high intratumoral heterogeneity in RB, consisting of 10 transcriptionally distinct subpopulations with varying levels of proliferation capacity. Our results uncovered a complex architecture of the tumor microenvironment that predominantly consisted of cone precursors, as well as glial cells and cancer-associated fibroblasts. We delineated the cell trajectory underlying malignant progression of RB, and identified key signaling pathways driving genetic regulation across RB progression. We also explored the signaling pathways mediating cell-cell communications in RB subpopulations, and mapped the spatial networks of RB subpopulations and region neighbors. Altogether, we constructed the first spatial gene atlas for RB, which allowed us to characterize the transcriptomic landscape in spatially-resolved RB subpopulations, providing novel insights into the complex spatial communications involved in RB progression.

show abstract

Cadherin 5 Ιs a Significant Risk Factor for Hematogenous Recurrence and a Prognostic Factor in Locally Advanced Gastric Cancer

Abstract: CDH5 may play a key role in hematogenous recurrence of advanced gastric cancer and may be a viable treatment target.

Cited by 4 publications

References 23 publications

Expression Profile and Prognostic Values of CDH Family Members in Lung Adenocarcinoma

Expression Profile and Prognostic Values of CDH Family Members in Lung Adenocarcinoma

GPR116 overexpression correlates with poor prognosis in gastric cancer

Spatial transcriptomic profiling of human retinoblastoma

Contact Info

Product

Resources

About